Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Biopharmaceutical

NJEDA: Ideal Location, Unique State Resources Give Enteris BioPharma Advantage in Global Marketplace

Trenton, NJ, June 25, 2017 — This week’s BIO International Convention gave leaders from New Jersey’s vast life sciences ecosystem the chance to show emerging companies the advantages of establishing themselves within the State, such as its ideal location on the Eastern seaboard and the large number of pharmaceutical giants that currently call the State “home.”

“The Garden State is truly the best place to start a biopharmaceutical company,” New Jersey Economic Development Authority (EDA) Chief Executive Officer (CEO) Melissa Orsen said. Continue reading

New Jersey Innovation Institute Introduces Two Groundbreaking Biopharmaceutical Centers

Newark, NJ, June 24, 2017 — Companies in every sector are realizing that manufacturing matters.  For the biopharmaceutical industry, innovation is not about reducing unit part costs; instead, process technology is a strategic tool to reduce time to market, ensure consistent product quality and streamline regulatory approval.

As rapidly as science is advancing drug discovery, so too, must production technology keep pace.  But where will such innovation happen?

The New Jersey Innovation Institute (NJII) is answering this question. Continue reading

GEN Publishes 2017 Top 10 U.S. Biopharma Clusters List; New Jersey/New York Again Ranked No. 3

New Rochelle, NY, June 22, 2017 — Genetic Engineering & Biotechnology News (GEN) on June 5 published its 2017 Top 10 US Biopharma Clusters list.  New Jersey/New York is number three on the list, the same position it was on GEN’s 2016 Top 10 list.

Greater Philadelphia ranks at number seven.

GEN’s Top 10 U.S. Biopharma Clusters are:

  1. Boston-Cambridge
  2. San Francisco Bay Area
  3. New Jersey/New York
  4. San Diego
  5. Maryland, Virginia and DC Metro
  6. San Diego
  7. Greater Philadelphia
  8. Seattle
  9. Raleigh/Durham (includes Research Triangle Park)
  10. Los Angeles/Orange County
  11. Chicagoland

Continue reading

Opinion: Labor Leader Greg Lalevee on ‘Workers Win When Jersey Drug Companies Innovate’

Greg Lalevee

Springfield, NJ, June 21, 2017The Record/NorthJersey.com on June 15 published the following opinion piece by Greg Lalevee, Business Manager, the International Union of Operating Engineers Local 825:

New Jersey’s nickname, “Medicine Chest of the World,” is backed up by the numbers.

Our state is home to more than 3,000 life sciences establishments.  Thirteen of the world’s top 20 biopharmaceutical companies have made the Garden State their U.S. headquarters.

These firms are innovating and saving lives every day — and they couldn’t do it without help from supportive government policies and New Jersey’s well-trained and talented union workforce. Continue reading

Three PhRMA Reports Highlight Increasing Global Competition in Biopharmaceutical R&D, Posing Challenges to Future U.S. Standing

Washington, DC, June 9, 2017 — As the U.S. looks to maintain its global leadership in biopharmaceutical research and development, three new reports point to an increasingly competitive global environment — one that requires a thorough assessment of our current public policies.

That includes the biopharmaceutical industry’s investments in science, technology, engineering and mathematics (STEM)-based initiatives at the state and national levels given the growing efforts of other countries to compete for the high-wage jobs and robust economic contributions of innovative biopharmaceutical companies.

“The American biopharmaceutical industry is the global leader in research and development (R&D) and has delivered many of the treatments and cures that have saved millions of lives around the world,” said Dr. Anne Pritchett, vice president, policy and research, at the Pharmaceutical Research and Manufacturers of America (PhRMA).  Continue reading

Opinion: PhRMA CEO Stephen J. Ubl on ‘How to Negotiate Better Deals for Prescription Medicines’

Stephen J. Ubl

Washington, DC, June 6, 2017Pharmaceutical Research and Manufacturers of America (PhRMA) President and Chief Executive Officer Stephen J. Ubl writes in Forbes:

The way our health care system currently pays for prescription medicines is convoluted and confusing.  We rely on a complicated system of list prices, net prices, rebates and an opaque supply chain that often results in uncertainty and frustration for patients.

It is no wonder consumers and policymakers have questions and are looking for better answers. So are we. Continue reading

With an Emphasis on R&D, PhRMA Board of Directors Establishes New Membership Criteria

Washington, DC, May 11, 2017 — Demonstrating its commitment to representing research- based biopharmaceutical companies, the board of directors for the Pharmaceutical Research and Manufacturers of America (PhRMA) on May 9 approved new criteria for membership.

Biopharmaceutical companies will now have to meet new research and development (R&D) requirements in order to be eligible to join PhRMA.

In making the announcement, Joaquin Duato, PhRMA board chairman and worldwide chairman, pharmaceuticals, Johnson & Johnson, said, “By putting in place new membership criteria, the board is sending a clear message that being a member of PhRMA means being committed to doing the time-intensive, scientifically sound research it takes to bring bold new advances in treatments and cures to patients.” Continue reading

Trump Administration Seeks to Hike Life Sciences Industry’s FDA User Fees Paid to Help Review, Approve Medical Advancements

Washington, DC, April 20, 2017 — Thomas M. Burton reported in The Wall Street Journal that a bipartisan bill in Congress calls for sharp increases in user fees paid by medical industries to the Food and Drug Administration (FDA) to bear the cost of reviewing brand-name and generic drugs, medical devices and a type of generics called biosimilars.

The total base fees for prescription drugs to be collected for fiscal year 2018 under the legislation would be about $878.8 million, up 22% from the current fiscal year’s amount of $718.7 million, according to congressional aides.

The payments from industry have previously accounted for 70% of the FDA’s brand-name drug review budget, 36% of the medical device review budget, 75% of the budget for generic drug reviews and 29% of that for biosimilars, which mimic complex biological drugs. Continue reading

I-ACT for Children Launches to Promote Innovative Medicines Development for Young Patients in Need

Washington, DC, April 19, 2017 — Lucy Vereshchagina reports on PhRMA’s Catalyst blog that, in an exciting step forward to support research and development of innovative new medicines and devices for pediatric patients, the Critical Path Institute (C-Path) announced the launch of a new nonprofit to address challenges in bringing new therapies to children in need.

Called the Institute for Advanced Clinical Trials for Children (I-ACT for Children), this new organization will seek to foster public-private collaboration in finding solutions to barriers to pediatric medicines development as well as improving the pediatric clinical trials process.

Specifically, it will work to optimize pediatric study designs, protocols, best practices, training and engagement of patients and parents to advance clinical trials to improve children’s health. Continue reading

Deloitte Report: Driving Medical Innovation Through Biopharmaceutical Collaboration.

Washington, DC, April 18, 2017 — Emma Van Hook, a director of Policy & Research at the Pharmaceutical Research and Manufacturers of America (PhRMA), reports on The Catalyst that a new report from Deloitte examines the changing landscape of biopharmaceutical research, as stakeholders across the research and development (R&D) ecosystem are increasingly coming together to tackle sciences’ most vexing health challenges.

The new research illustrates there has been a significant shift in recent years from traditional, asset-based or transactional agreements to more open, collaborative approaches for conducting biopharmaceutical research.

Deloitte compiled and analyzed a database of thousands of partnerships initiated between 1995 and 2014. Continue reading